Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review

ABSTRACT In this article, recent progress in cardiotoxicity testing based on the use of immortalized cell lines or human embryonic stem cell (hESC) derived cardiomyocytes in combination with state‐of‐the‐art bioanalytical methods and sensors is reviewed. The focus is on hESC‐derived cells and their refinement into competent testing cells, but the access and utility of other relevant cell types are also discussed. Recent developments in sensor techniques and bioanalytical approaches for measuring critical cardiotoxicity parameters are highlighted, together with aspects of data evaluation and validation. Finally, recommendations for further research are given. Copyright © 2011 John Wiley & Sons, Ltd. Recent progress in cardiotoxicity testing based on the use of human embryonic stem cell (hESC) derived cardiomyocytes in combination with state‐of‐the‐art bioanalytical sensor methods is reviewed. The focus is on hESC‐derived cells and their refinement into competent testing cells, but the access and utility of other relevant cell types are also discussed. Developments in sensor techniques for measuring critical cardiotoxicity parameters are highlighted, together with aspects of data evaluation and validation. Conclusive recommendations for further research are given.